U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Primary Peritoneal Adenocarcinoma

MedGen UID:
1750087
•Concept ID:
C5418918
•
Neoplastic Process

Definition

Primary peritoneal adenocarcinoma that is resistant to treatment. [from NCI]

Recent clinical studies

Etiology

HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K
BMC Cancer 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. PMID: 32532230Free PMC Article
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W
Lancet Gastroenterol Hepatol 2017 Apr;2(4):277-287. Epub 2017 Jan 19 doi: 10.1016/S2468-1253(16)30219-9. PMID: 28404157
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D
J Clin Oncol 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20 doi: 10.1200/JCO.2015.65.1901. PMID: 27325864Free PMC Article
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C
Gynecol Oncol 2010 Feb;116(2):157-62. doi: 10.1016/j.ygyno.2009.10.076. PMID: 20109725

Diagnosis

Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto.
Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T, Del Chiaro M, Jang JY, Gulla A, Yoon YS, Shan YS, Lou W, Valente R, Furuse J, Oba A, Nagai M, Terai T, Tanaka H, Sakai A, Yamamoto T, Yamaki S, Matsumoto I, Murakami Y, Takaori K, Takeyama Y
Pancreatology 2023 Sep;23(6):682-688. Epub 2023 Jul 20 doi: 10.1016/j.pan.2023.07.005. PMID: 37507301
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C
Gynecol Oncol 2010 Feb;116(2):157-62. doi: 10.1016/j.ygyno.2009.10.076. PMID: 20109725
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM
J Clin Oncol 2003 Jan 15;21(2):291-7. doi: 10.1200/JCO.2003.02.091. PMID: 12525521
Field cancerization: why late "recurrent" ovarian cancer is not recurrent.
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ
Am J Obstet Gynecol 1998 Apr;178(4):641-9. doi: 10.1016/s0002-9378(98)70473-9. PMID: 9579425

Therapy

Surgery for ulcerative colitis complicated with colorectal cancer: when ileal pouch-anal anastomosis is the right choice.
Tonelli F, Di Martino C, Amorosi A, Mini E, Nesi G
Updates Surg 2022 Apr;74(2):637-647. Epub 2022 Feb 25 doi: 10.1007/s13304-022-01250-4. PMID: 35217982Free PMC Article
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report.
Massaccesi M, Boldrini L, Romano A, Rossi E, Schinzari G, Lepre E, Gambacorta MA, Valentini V
Immunotherapy 2021 Dec;13(18):1457-1463. Epub 2021 Oct 19 doi: 10.2217/imt-2020-0289. PMID: 34664999
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K
BMC Cancer 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. PMID: 32532230Free PMC Article
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C
Gynecol Oncol 2010 Feb;116(2):157-62. doi: 10.1016/j.ygyno.2009.10.076. PMID: 20109725

Prognosis

Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto.
Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T, Del Chiaro M, Jang JY, Gulla A, Yoon YS, Shan YS, Lou W, Valente R, Furuse J, Oba A, Nagai M, Terai T, Tanaka H, Sakai A, Yamamoto T, Yamaki S, Matsumoto I, Murakami Y, Takaori K, Takeyama Y
Pancreatology 2023 Sep;23(6):682-688. Epub 2023 Jul 20 doi: 10.1016/j.pan.2023.07.005. PMID: 37507301
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K
BMC Cancer 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. PMID: 32532230Free PMC Article
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E
Br J Cancer 2019 Aug;121(5):378-383. Epub 2019 Jul 31 doi: 10.1038/s41416-019-0537-z. PMID: 31363167Free PMC Article
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774
Field cancerization: why late "recurrent" ovarian cancer is not recurrent.
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ
Am J Obstet Gynecol 1998 Apr;178(4):641-9. doi: 10.1016/s0002-9378(98)70473-9. PMID: 9579425

Clinical prediction guides

Surgery for ulcerative colitis complicated with colorectal cancer: when ileal pouch-anal anastomosis is the right choice.
Tonelli F, Di Martino C, Amorosi A, Mini E, Nesi G
Updates Surg 2022 Apr;74(2):637-647. Epub 2022 Feb 25 doi: 10.1007/s13304-022-01250-4. PMID: 35217982Free PMC Article
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report.
Massaccesi M, Boldrini L, Romano A, Rossi E, Schinzari G, Lepre E, Gambacorta MA, Valentini V
Immunotherapy 2021 Dec;13(18):1457-1463. Epub 2021 Oct 19 doi: 10.2217/imt-2020-0289. PMID: 34664999
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E
Br J Cancer 2019 Aug;121(5):378-383. Epub 2019 Jul 31 doi: 10.1038/s41416-019-0537-z. PMID: 31363167Free PMC Article
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R
Cancer Discov 2011 Dec;1(7):573-9. doi: 10.1158/2159-8290.CD-11-0175. PMID: 22389872Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...